Brief: Statera Biopharma Advances Next-Gen Proprietary Compositions Based On STAT-200 Platform
07/03/2022 12:35
March 7 (Reuters) - Statera Biopharma Inc STAB.O :
* STATERA BIOPHARMA ADVANCES NEXT-GEN PROPRIETARY COMPOSITIONS BASED ON
STAT-200
PLATFORM
Source text for Eikon: ID:nGNXsntgB
Further company coverage: STAB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Statera Biopharma
See all news20/20 Biolabs jumps on Ebola, hantavirus testing plans
Tivic Health Systems rises after deal for late-stage immunotherapy drug
Brief: Tivic Health Acquires Exclusive Worldwide Rights To Phase III TLR5 Agonist
Brief: Statera Biopharma Inc Quarterly Loss Per Share $0.20
Brief: Statera Biopharma Inc - On October 12, 2022, Co Entered A Binding Memorandum Of Understanding (“MoU”) With Holobeam Technologies, Inc